{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:04:49Z","timestamp":1788177889059,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["20224BAB216019"],"award-info":[{"award-number":["20224BAB216019"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Nanchang University","award":["2022YNFY12010"],"award-info":[{"award-number":["2022YNFY12010"]}]},{"name":"General Science and Technology Plan of Jiangxi Provincial Health Commission","award":["202410034"],"award-info":[{"award-number":["202410034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71908-z","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:04:06Z","timestamp":1726045446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Blood PAI-1 and cardiovascular and metabolic risk factors among the middle-aged women from SWAN study"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhenyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"8","key":"71908_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/S2213-8587(14)70040-3","volume":"2","author":"RR Huxley","year":"2014","unstructured":"Huxley, R. R. & Perkovic, V. The modifiable burden of worldwide mortality from cardiovascular diseases. Lancet Diabetes Endocrinol. 2(8), 604\u2013606. https:\/\/doi.org\/10.1016\/S2213-8587(14)70040-3 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"71908_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1161\/CIRCULATIONAHA.118.038137","volume":"139","author":"JR Petrie","year":"2019","unstructured":"Petrie, J. R. & Sattar, N. excess cardiovascular risk in type 1 diabetes mellitus. Circulation 139(6), 744\u2013747. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038137 (2019).","journal-title":"Circulation"},{"issue":"7","key":"71908_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCRESAHA.118.312498","volume":"123","author":"AE Kane","year":"2018","unstructured":"Kane, A. E. & Sinclair, D. A. Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases. Circ. Res. 123(7), 868\u2013885. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312498 (2018).","journal-title":"Circ. Res."},{"issue":"10","key":"71908_CR4","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.metabol.2015.07.013","volume":"64","author":"I Agarwal","year":"2015","unstructured":"Agarwal, I. et al. Associations between metabolic dysregulation and circulating biomarkers of fibrosis: The Cardiovascular Health Study. Metabolism 64(10), 1316\u20131323. https:\/\/doi.org\/10.1016\/j.metabol.2015.07.013 (2015).","journal-title":"Metabolism"},{"issue":"12","key":"71908_CR5","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin, E. J. et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation 137(12), e67\u2013e492. https:\/\/doi.org\/10.1161\/CIR.0000000000000558 (2018).","journal-title":"Circulation"},{"issue":"2","key":"71908_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11906-018-0812-z","volume":"20","author":"MG Saklayen","year":"2018","unstructured":"Saklayen, M. G. The global epidemic of the metabolic syndrome. Curr. Hypertens Rep. 20(2), 12. https:\/\/doi.org\/10.1007\/s11906-018-0812-z (2018).","journal-title":"Curr. Hypertens Rep."},{"issue":"9","key":"71908_CR7","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1210\/jcem.84.9.5987","volume":"84","author":"DL Crandall","year":"1999","unstructured":"Crandall, D. L. et al. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J. Clin. Endocrinol. Metab. 84(9), 3222\u20133227. https:\/\/doi.org\/10.1210\/jcem.84.9.5987 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"71908_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/jcp.44.2.139","volume":"44","author":"AJ Simpson","year":"1991","unstructured":"Simpson, A. J., Booth, N. A., Moore, N. R. & Bennett, B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J. Clin. Pathol. 44(2), 139\u2013143. https:\/\/doi.org\/10.1136\/jcp.44.2.139 (1991).","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"71908_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1073\/pnas.022608799","volume":"99","author":"K Yamamoto","year":"2002","unstructured":"Yamamoto, K. et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: Implications for stress-induced thrombosis in aged individuals. Proc. Natl. Acad. Sci. USA 99(2), 890\u2013895. https:\/\/doi.org\/10.1073\/pnas.022608799 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"71908_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","volume":"5","author":"RG Jung","year":"2018","unstructured":"Jung, R. G. et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb. J. 5(16), 12. https:\/\/doi.org\/10.1186\/s12959-018-0166-4 (2018).","journal-title":"Thromb. J."},{"issue":"6","key":"71908_CR11","doi-asserted-by":"publisher","first-page":"e004918","DOI":"10.1161\/JAHA.116.004918","volume":"6","author":"C Song","year":"2017","unstructured":"Song, C., Burgess, S., Eicher, J. D., O\u2019Donnell, C. J. & Johnson, A. D. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J. Am. Heart Assoc. 6(6), e004918. https:\/\/doi.org\/10.1161\/JAHA.116.004918 (2017).","journal-title":"J. Am. Heart Assoc."},{"issue":"25","key":"71908_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","volume":"313","author":"A Hamsten","year":"1985","unstructured":"Hamsten, A., Wiman, B., de Faire, U. & Blomb\u00e4ck, M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313(25), 1557\u20131563. https:\/\/doi.org\/10.1056\/NEJM198512193132501 (1985).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"71908_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood-2010-02-267740","volume":"116","author":"ME Meltzer","year":"2010","unstructured":"Meltzer, M. E. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 116(1), 113\u2013121. https:\/\/doi.org\/10.1182\/blood-2010-02-267740 (2010).","journal-title":"Blood"},{"issue":"1","key":"71908_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/jim-2017-000468","volume":"66","author":"A Carratala","year":"2018","unstructured":"Carratala, A. et al. PAI-1 levels are related to insulin resistance and carotid atherosclerosis in subjects with familial combined hyperlipidemia. J. Investig. Med. 66(1), 17\u201321. https:\/\/doi.org\/10.1136\/jim-2017-000468 (2018).","journal-title":"J. Investig. Med."},{"issue":"12","key":"71908_CR15","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.2174\/138945011797635803","volume":"12","author":"VA Ploplis","year":"2011","unstructured":"Ploplis, V. A. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr. Drug Targets. 12(12), 1782\u20131789. https:\/\/doi.org\/10.2174\/138945011797635803 (2011).","journal-title":"Curr. Drug Targets."},{"issue":"7","key":"71908_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF00403280","volume":"34","author":"I Juhan-Vague","year":"1991","unstructured":"Juhan-Vague, I., Alessi, M. C. & Vague, P. Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis. Diabetologia 34(7), 457\u2013462. https:\/\/doi.org\/10.1007\/BF00403280 (1991).","journal-title":"Diabetologia"},{"issue":"6","key":"71908_CR17","doi-asserted-by":"publisher","first-page":"17714","DOI":"10.1038\/srep17714","volume":"27","author":"J Yarmolinsky","year":"2016","unstructured":"Yarmolinsky, J. et al. Plasminogen activator inhibitor-1 and type 2 diabetes: A systematic review and meta-analysis of observational studies. Sci. Rep. 27(6), 17714. https:\/\/doi.org\/10.1038\/srep17714 (2016).","journal-title":"Sci. Rep."},{"issue":"4","key":"71908_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","volume":"51","author":"A Festa","year":"2002","unstructured":"Festa, A., D\u2019Agostino, R. Jr., Tracy, R. P., Haffner, S. M., Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 51(4), 1131\u20131137. https:\/\/doi.org\/10.2337\/diabetes.51.4.1131 (2002).","journal-title":"Diabetes"},{"issue":"12","key":"71908_CR19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/hep4.1259","volume":"2","author":"AS Henkel","year":"2018","unstructured":"Henkel, A. S., Khan, S. S., Olivares, S., Miyata, T. & Vaughan, D. E. Inhibition of plasminogen activator inhibitor 1 attenuates hepatic steatosis but does not prevent progressive nonalcoholic steatohepatitis in mice. Hepatol. Commun. 2(12), 1479\u20131492. https:\/\/doi.org\/10.1002\/hep4.1259 (2018).","journal-title":"Hepatol. Commun."},{"issue":"10","key":"71908_CR20","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1096\/fj.00-0750fje","volume":"15","author":"K Sch\u00e4fer","year":"2001","unstructured":"Sch\u00e4fer, K., Fujisawa, K., Konstantinides, S. & Loskutoff, D. J. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob\/ob mice. FASEB J. 15(10), 1840\u20131842. https:\/\/doi.org\/10.1096\/fj.00-0750fje (2001).","journal-title":"FASEB J."},{"issue":"2","key":"71908_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2337\/diabetes.53.2.336","volume":"53","author":"LJ Ma","year":"2004","unstructured":"Ma, L. J. et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53(2), 336\u2013346. https:\/\/doi.org\/10.2337\/diabetes.53.2.336 (2004).","journal-title":"Diabetes"},{"key":"71908_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/B978-012453790-3\/50012-3","volume-title":"Menopause: Biology and Pathobiology","author":"MF Sowers","year":"2000","unstructured":"Sowers, M. F. et al. SWAN: A multicenter, multiethnic, community-based cohort study of women and the menopausal transition. In Menopause: Biology and Pathobiology (eds Lobo, R. et al.) 175\u2013188 (Academic Press, 2000)."},{"issue":"4","key":"71908_CR23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/cphy.c150006","volume":"5","author":"NG Frangogiannis","year":"2015","unstructured":"Frangogiannis, N. G. Pathophysiology of myocardial infarction. Compr. Physiol. 5(4), 1841\u20131875. https:\/\/doi.org\/10.1002\/cphy.c150006 (2015).","journal-title":"Compr. Physiol."},{"issue":"4","key":"71908_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/jth.13641","volume":"15","author":"AC J\u00f6nsson Rylander","year":"2017","unstructured":"J\u00f6nsson Rylander, A. C. et al. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque. J. Thromb. Haemost. 15(4), 758\u2013769. https:\/\/doi.org\/10.1111\/jth.13641 (2017).","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"71908_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s0008-6363(97)00144-2","volume":"36","author":"T Padr\u00f3","year":"1997","unstructured":"Padr\u00f3, T. et al. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc. Res. 36(1), 28\u201336. https:\/\/doi.org\/10.1016\/s0008-6363(97)00144-2 (1997).","journal-title":"Cardiovasc. Res."},{"issue":"15","key":"71908_CR26","doi-asserted-by":"publisher","first-page":"6998","DOI":"10.1073\/pnas.89.15.6998","volume":"89","author":"J Schneiderman","year":"1992","unstructured":"Schneiderman, J. et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA 89(15), 6998\u20137002. https:\/\/doi.org\/10.1073\/pnas.89.15.6998 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"71908_CR27","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1161\/STROKEAHA.106.479642","volume":"38","author":"T Ninomiya","year":"2007","unstructured":"Ninomiya, T. et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study. Stroke 38(7), 2063\u20132069. https:\/\/doi.org\/10.1161\/STROKEAHA.106.479642 (2007).","journal-title":"Stroke"},{"issue":"3","key":"71908_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1055\/s-0038-1646997","volume":"60","author":"MC Alessi","year":"1988","unstructured":"Alessi, M. C., Juhan-Vague, I., Kooistra, T., Declerck, P. J. & Collen, D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb. Haemost. 60(3), 491\u2013494 (1988).","journal-title":"Thromb. Haemost."},{"issue":"1","key":"71908_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2006.12.025","volume":"196","author":"H Iwasaki","year":"2008","unstructured":"Iwasaki, H. et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho\/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis 196(1), 22\u201328. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.12.025 (2008).","journal-title":"Atherosclerosis"},{"issue":"12","key":"71908_CR30","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1161\/01.atv.20.12.2696","volume":"20","author":"Y Chen","year":"2000","unstructured":"Chen, Y., Billadello, J. J. & Schneider, D. J. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler. Thromb. Vasc. Biol. 20(12), 2696\u20132701. https:\/\/doi.org\/10.1161\/01.atv.20.12.2696 (2000).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"18","key":"71908_CR31","doi-asserted-by":"publisher","first-page":"12412","DOI":"10.1016\/S0021-9258(18)42289-2","volume":"267","author":"PG Fattal","year":"1992","unstructured":"Fattal, P. G., Schneider, D. J., Sobel, B. E. & Billadello, J. J. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J. Biol. Chem. 267(18), 12412\u201312415 (1992).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"71908_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.2337\/diab.46.5.860","volume":"46","author":"MC Alessi","year":"1997","unstructured":"Alessi, M. C. et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46(5), 860\u2013867. https:\/\/doi.org\/10.2337\/diab.46.5.860 (1997).","journal-title":"Diabetes"},{"issue":"4","key":"71908_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1172\/JCI115440","volume":"88","author":"MS Sawdey","year":"1991","unstructured":"Sawdey, M. S. & Loskutoff, D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J. Clin. Invest. 88(4), 1346\u20131353. https:\/\/doi.org\/10.1172\/JCI115440 (1991).","journal-title":"J. Clin. Invest."},{"issue":"15","key":"71908_CR34","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1161\/01.CIR.0000161823.55935.BE","volume":"111","author":"G Rega","year":"2005","unstructured":"Rega, G. et al. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111(15), 1938\u20131945. https:\/\/doi.org\/10.1161\/01.CIR.0000161823.55935.BE (2005).","journal-title":"Circulation"},{"issue":"2018","key":"71908_CR35","doi-asserted-by":"publisher","first-page":"9596054","DOI":"10.1155\/2018\/9596054","volume":"30","author":"S Somodi","year":"2018","unstructured":"Somodi, S. et al. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int. J. Endocrinol. 30(2018), 9596054. https:\/\/doi.org\/10.1155\/2018\/9596054 (2018).","journal-title":"Int. J. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71908-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71908-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T09:09:27Z","timestamp":1726045767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71908-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71908"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71908-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by The Institutional Review Board (IRB) at each Study of Women\u2019s Health Across the Nation (SWAN) site and Data Coordinating Center, and informed consent was obtained from all included individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"21207"}}